JP2014507476A5 - - Google Patents

Download PDF

Info

Publication number
JP2014507476A5
JP2014507476A5 JP2013557816A JP2013557816A JP2014507476A5 JP 2014507476 A5 JP2014507476 A5 JP 2014507476A5 JP 2013557816 A JP2013557816 A JP 2013557816A JP 2013557816 A JP2013557816 A JP 2013557816A JP 2014507476 A5 JP2014507476 A5 JP 2014507476A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
uric acid
gout
composition according
hyperuricemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013557816A
Other languages
English (en)
Japanese (ja)
Other versions
JP6012639B2 (ja
JP2014507476A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/027993 external-priority patent/WO2012125359A1/en
Publication of JP2014507476A publication Critical patent/JP2014507476A/ja
Publication of JP2014507476A5 publication Critical patent/JP2014507476A5/ja
Application granted granted Critical
Publication of JP6012639B2 publication Critical patent/JP6012639B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013557816A 2011-03-11 2012-03-07 高尿酸血症および高尿酸血症関連代謝障害を治療するための方法および組成物 Expired - Fee Related JP6012639B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161451600P 2011-03-11 2011-03-11
US61/451,600 2011-03-11
PCT/US2012/027993 WO2012125359A1 (en) 2011-03-11 2012-03-07 Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Publications (3)

Publication Number Publication Date
JP2014507476A JP2014507476A (ja) 2014-03-27
JP2014507476A5 true JP2014507476A5 (enExample) 2015-04-23
JP6012639B2 JP6012639B2 (ja) 2016-10-25

Family

ID=46796094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013557816A Expired - Fee Related JP6012639B2 (ja) 2011-03-11 2012-03-07 高尿酸血症および高尿酸血症関連代謝障害を治療するための方法および組成物

Country Status (16)

Country Link
US (1) US8865689B2 (enExample)
EP (1) EP2683372B1 (enExample)
JP (1) JP6012639B2 (enExample)
KR (1) KR101567885B1 (enExample)
CN (1) CN103429236B (enExample)
AR (1) AR085662A1 (enExample)
AU (1) AU2012229443B2 (enExample)
BR (1) BR112013022332A2 (enExample)
CA (1) CA2829101C (enExample)
ES (1) ES2634562T3 (enExample)
IL (1) IL228030B (enExample)
MX (1) MX350666B (enExample)
PT (1) PT2683372T (enExample)
RU (1) RU2603050C2 (enExample)
TW (1) TWI505827B (enExample)
WO (1) WO2012125359A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2560310T3 (es) * 2010-04-08 2016-02-18 Twi Biotechnology, Inc. Métodos de uso de diacereína como una terapia concomitante para diabetes
AU2012229443B2 (en) 2011-03-11 2017-03-02 Twi Biotechnology, Inc. Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
CN103638020A (zh) * 2013-12-20 2014-03-19 中美华世通生物医药科技(武汉)有限公司 一种治疗痛风的新型药物组合物
CN104491839B (zh) * 2014-11-27 2016-06-22 青岛大学附属医院 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途
KR101647348B1 (ko) * 2014-12-30 2016-08-22 충남대학교산학협력단 Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물
MX2017013489A (es) * 2015-04-20 2018-05-22 Twi Biotechnology Inc Formulaciones que contienen diacereina y metodos para la reduccion de los niveles en sangre de acido urico usando los mismos.
US20160303050A1 (en) * 2015-04-20 2016-10-20 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
TWI684465B (zh) * 2015-04-22 2020-02-11 安成生物科技股份有限公司 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
MX373702B (es) 2015-07-01 2020-05-07 Twi Biotechnology Inc Formulaciones topicas de diacereina o rheina y sus usos.
MX2018002049A (es) * 2015-08-17 2018-06-15 Twi Biotechnology Inc Diacereina o sus analogos para inhibir la expresion de proteina como mota relacionada a la apoptosis que contiene un dominio de reclutamiento de caspasa (asc), expresion de dominios de pirina y familia nlr que contienen 3 (nlrp3) y/o formacion de complejo de inflamasoma de nlrp3.
KR101863604B1 (ko) * 2016-04-08 2018-06-04 한국 한의학 연구원 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
CN107468955B (zh) * 2017-09-06 2020-07-24 大连医科大学 治疗痛风性关节炎的中药及制备方法
KR102361526B1 (ko) * 2019-07-02 2022-02-11 한국 한의학 연구원 난각막을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
CN113082012A (zh) * 2021-04-26 2021-07-09 北京亿药科技有限公司 紫苏烯在制备预防和/或治疗高尿酸血症药物中的应用
US12269875B2 (en) * 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009698A (es) * 2004-10-04 2006-04-05 Maria Elena Garcia Armenta Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam.
DK2124997T3 (da) * 2006-10-20 2012-08-27 Regeneron Pharma Anvendelse af IL-1-antagonister til behandling af gigt og pseudogigt
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
EP2471517A3 (en) * 2007-09-14 2012-12-26 Wockhardt Limited Rhein or diacerein compositions
US20100150938A1 (en) * 2008-07-03 2010-06-17 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因(diacerein)之醫藥組合物
AU2012229443B2 (en) 2011-03-11 2017-03-02 Twi Biotechnology, Inc. Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Similar Documents

Publication Publication Date Title
JP2014507476A5 (enExample)
RU2013145498A (ru) Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией
Yang et al. The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
CR10455A (es) Compuestos farmaceuticos
JP2017513836A5 (enExample)
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
SG10201407013QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
HK1206264A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
NZ602029A (en) Use of meloxicam for the long-term treatment of kidney disorders in cats
JP2017505285A5 (enExample)
AR082167A1 (es) Formas de dosificacion gastrorretentivas
JP2020500875A5 (enExample)
AR059575A1 (es) Metodo para el tratamiento de enfermedades inflamatorias
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
AR075179A1 (es) Formulaciones galenicas de compuestos organicos que comprenden alisquireno
JP2009138003A5 (enExample)
JP2013209384A5 (enExample)
JP2012520883A5 (enExample)
HRP20171743T1 (hr) Sastavi i postupci za savladavanje otpornosti na tramadol
JP2018533560A5 (enExample)
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
HRP20130007T1 (hr) Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli
JP2016512817A5 (enExample)
JP2017508817A5 (enExample)